(Q40139934)
Statements
1 reference
A new model to evaluate the long-term cost effectiveness of orphan and highly specialised drugs following listing on the Australian Pharmaceutical Benefits Scheme: the Bosentan Patient Registry (English)
1 reference
Aj Owen
1 reference
J Spinks
1 reference
A Meehan
1 reference
T Robb
1 reference
M Hardy
1 reference
D Kwasha
1 reference
J Wlodarczyk
1 reference
Cm Reid
1 reference
1 January 2008
1 reference
1 reference
11
1 reference
2
1 reference
235-243
1 reference
Identifiers
1 reference
1 reference